AUTHORS
Ronin Joshua So Cosiquien, BS, Krishna Chaitanya Allam, BMsc2, Sai Anoop Dhamera, BS3, Hani Hassoun, MD4, Edgar Jaimes5, Abhijat Kitchlu6, Heather J. Landau, MD7, Ming Shen, BA8, Veronica Torres9, Sabine Karam, MD10
AFFILIATIONS
1 University of Minnesota, Minneapolis, Minnesota, United States
2 University of Minnesota, Minneapolis, Minnesota, United States
3 University of Minnesota, Minneapolis, Minnesota, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 University of Toronto, Toronto, Canada
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 University of Minnesota, Minneapolis, Minnesota, United States
9 University of Sao Paulo, Sao Paulo, Brazil
10 University of Minnesota, Minneapolis, Minnesota, United States
ABSTRACT
BACKGROUND
The Revised International Staging System (R-ISS) is the standard prognostic framework for newly diagnosed multiple myeloma (MM), yet host-level metabolic derangements that may contribute to survival heterogeneity within stages remain understudied. Metabolic acidosis is common at MM diagnosis — driven by light chain–mediated tubular injury and other mechanisms — but its independent prognostic significance after adjustment for renal function and tumor-biology-based staging has not been established. We investigated whether acidosis at diagnosis carries prognostic information independent of and complementary to R-ISS.
METHODS
In a single-center retrospective cohort of 293 patients with newly diagnosed MM (March 2009–January 2024, University of Minnesota; median follow-up 60.0 months), we evaluated overall survival (OS) from treatment initiation, censored at 5 years or December 31, 2025. Metabolic acidosis was defined as serum bicarbonate <22 mmol/L; renal impairment was defined per International Myeloma Working Group (IMWG) criteria (creatinine ≥2.0 mg/dL or eGFR ≤40 mL/min/1.73 m²). A multivariable Cox proportional hazards model assessed associations of metabolic acidosis, age, sex, renal impairment, diabetes, R-ISS stage, and IgA heavy chain status with OS. Missing data were addressed by multiple imputations by chained equations (MICE, 30 datasets) with Rubin's rules pooling. Sensitivity analyses substituted continuous eGFR for binary renal impairment and adjusted for autologous stem cell transplantation (ASCT). Hyponatremia (defined as < 130 mEq/L), hyperkalemia (defined as > 5 mEq/L), and anion gap were each tested as individual additions to the primary model to assess specificity. A 2-factor risk score (metabolic acidosis and diabetes: 0 vs. ≥1 factors) was compared with R-ISS by Harrell's concordance index (C-index) and Spearman correlation.
RESULTS
Among 293 patients (median age 65.0 years [IQR 58.0–71.0]; 62.1% male; 86.7% White; 65.9% ASCT recipients; 74 deaths [25.3%]), metabolic acidosis was present in 14.8% and diabetes in 12.0%. Metabolic acidosis was independently associated with inferior OS (HR 2.60, 95% CI 1.31–5.16; P = 0.007) after adjustment for all covariates. This association was not explained by graded renal dysfunction: acidosis remained significant when continuous eGFR replaced binary renal impairment (HR 2.46, 95% CI 1.24–4.79; P = 0.009), and bicarbonate correlated only moderately with eGFR (Pearson r = 0.42). Acidosis also remained significant after ASCT adjustment (HR 2.33, 95% CI 1.19–4.56; P = 0.014).
The prognostic signal was specific to acidosis: hyponatremia (P = 0.638), hyperkalemia (P = 0.623), and anion gap (P = 0.354) were not independently associated with OS, and anion gap did not outperform acidosis when substituted for it (HR 1.08, P = 0.177 vs. HR 2.60, P = 0.007). Other covariates independently associated with OS included diabetes (HR 2.69, 95% CI 1.51–4.79; P = 0.001), R-ISS stage (HR 1.96 per stage, 95% CI 1.32–2.91; P = 0.001), IgA heavy chain (HR 1.94, 95% CI 1.16–3.25; P = 0.013), and age (HR 1.05 per year, 95% CI 1.03–1.08; P < 0.001). Renal impairment was not independently significant (HR 0.63, 95% CI 0.32–1.25; P = 0.179). Full model discrimination was good (C-index 0.736).
A 2-factor stratification using acidosis and diabetes (≥1 vs. 0 factors) yielded an unadjusted HR of 2.57 (95% CI 1.57–4.19; P < 0.001), with pooled 3-year OS of 70.2% (95% CI 57.6–79.7%) versus 84.4% (95% CI 78.6–88.8%). This score was minimally correlated with R-ISS (Spearman ρ = 0.069), and a combined model improved discrimination beyond either alone (C-index 0.658 vs. 0.604 for R-ISS and 0.603 for the 2-factor score individually).
CONCLUSIONS
Metabolic acidosis at diagnosis is independently associated with inferior OS in newly diagnosed MM — an association that persists after adjustment for renal function, R-ISS stage, and other established prognostic factors, and is not explained by graded renal dysfunction. The near-zero correlation between a simple metabolic risk score incorporating acidosis and R-ISS, together with improved discrimination when combined, suggests that acidosis captures prognostic information independent of tumor-biology-based staging. External validation is warranted to determine whether this readily available biomarker can improve risk stratification in MM.
DISCLOSURES
Ronin Joshua So Cosiquien, BS: No relevant conflicts of interest to declare.